CD276 and breast cancer: At different E:T ratios, CD276 CAR-T showed high killing efficiency (cytolysis > 80%) against different human cancer cell lines, including liver cancer, glioma, renal cancer, fibrosarcoma, breast cancer, ovarian cancer and colon cancer (Supplementary Fig. 1b).